phenytoin has been researched along with olanzapine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Crismon, ML; Dorson, PG; Lee, JW | 1 |
| Janowsky, DS | 1 |
| Abu-Kishk, I; Berkovitch, M; Daniel, D; Reis, A; Toledano, M | 1 |
| de Castella, A; Fitzgerald, P; Gilbert, H; Gurvich, C; Kulkarni, J; Marston, N; McCauley-Elsom, K | 1 |
| Rosini, JM; Whyte, CJ | 1 |
2 review(s) available for phenytoin and olanzapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New treatments of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Lamotrigine; Olanzapine; Phenytoin; Pirenzepine; Topiramate; Treatment Outcome; Triazines | 1999 |
12 other study(ies) available for phenytoin and olanzapine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Seizure associated with olanzapine.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Drug Interactions; Female; Haloperidol; Humans; Olanzapine; Phenytoin; Pirenzepine; Seizures | 1999 |
Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic.
Topics: Acute Disease; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Blood Cell Count; Child; Dibenzothiazepines; Electroencephalography; False Positive Reactions; Humans; Magnetic Resonance Imaging; Male; Neuroleptic Malignant Syndrome; Neurologic Examination; Olanzapine; Phenytoin; Prion Diseases; Psychotic Disorders | 2004 |
Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy.
Topics: Adult; Antipsychotic Agents; Australia; Benzodiazepines; Chlorpromazine; Cross-Sectional Studies; Data Collection; Female; Humans; Infant, Newborn; Olanzapine; Phenytoin; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Psychotic Disorders; Registries; Risk Factors; Substance Withdrawal Syndrome; Suicide | 2008 |
Dantrolene for Treatment of Suspected Neuroleptic Malignant Syndrome.
Topics: Analgesics, Opioid; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Dantrolene; Diagnosis, Differential; Fentanyl; Haloperidol; Humans; Levetiracetam; Male; Middle Aged; Neuroleptic Malignant Syndrome; Olanzapine; Phenytoin; Piracetam | 2018 |